Who We Are
As the world's leading provider of generic drugs, Teva Pharmaceuticals understands the importance of making safe, quality medications accessible —and affordable.
At Teva, we continually evaluate and pursue growth opportunities that advance our goal of being a stronger, more diversified organization with the scale and resources to drive value across our business today and in the future. With the acquisition of Actavis Generics in 2016, our company now offers the richest product pipeline in the generic industry and will continue to lead the way with complementary technologies and product portfolios, offering more differentiated and durable products than any other generic company of this scale.
One in ten of the 3.66 billion generic prescriptions written in the United States is filled with a Teva product.1 Teva helped contribute to the $42 billon dollars in savings in U.S. healthcare by providing affordable generic drugs in 2018!2
Teva manufactures more than 500 generic prescription and over-the-counter products in more than 2,000 dosage strengths and package sizes, including oral solid dosage forms, injectable products, inhaled products, liquids, ointments and creams.2 Additionally, Teva employs nearly 6,800 employees in the United States and owns or leases approximately 10 facilities in North America.2
Teva Pharmaceuticals USA is subsidiary Teva Pharmaceutical Industries Ltd., headquartered in Israel, the global leader in generics and one of the world's leading pharmaceutical companies.
Learn more about our history and how we have grown to be the leading provider of generic drugs.
Choosing Teva Generics is choosing to enjoy the benefits only Teva can provide. Learn more about our advantages.
1. IQVIA NPA Data (as of MAT September 2020) on file at Teva.
2. Internal Data on File